Wednesday, April 15, 2015 6:07:08 AM
NEW YORK, NY--(Marketwired - May 30, 2014) - Daxor Corporation (NYSE MKT: DXR) -- The Journal of the American College of Cardiology - Heart Failure has published the first study measuring congestive heart failure patients' blood volumes at the initiation of treatment and just prior to discharge. The authors were Wayne L. Miller, MD, PhD, and Brian P. Mullan, MD. The Mayo Clinic's cardiology department is ranked #2 in the annual survey of U.S. hospitals for 2013 - 2014 according to the U.S. News and World Report.
This study involved 26 Class III/IV cardiac patients who are usually treated without blood volume measurements on the basis of clinical evaluations and tests such as hematocrits/hemoglobins, which measure the ratio of a patient's red cells but not the actual volume of a patient's blood. Retention of sodium and water and expansion of a patient's blood volume are the most fundamental derangements which occur in congestive heart failure patients. Treatment is usually based on clinical evaluations and other tests which do not measure the patient's blood volume.
The study was designed to quantitate total blood volume in patients hospitalized for decompensated heart failure and to determine the extent of volume overload and the magnitude and distribution of blood volume and water changes during diuretic therapy. Total blood volume analysis demonstrates a wide range in the extent of volume overload.
24 out of 26 patients were hypervolemic, with a range of +9.5% to +107% above the normal volume. By measuring blood volume at discharge, it was possible to compute whether the fluids removed were from the blood volume itself or from the interstitial fluid, which is the body fluid surrounding the cells of the body. On average 85% of the fluid removed came from the interstitial space. However, there was a wide range of variability within the patient population. The authors also noted that at discharge, despite vigorous therapy, most of the patients still had abnormally expanded blood volumes.
The authors noted "The extent of composition and distribution of volume overload are highly variable in decompensated congestive heart failure and this variability needs to be taken into account in the approach to individualized therapy. The authors further noted that "Utilizing current methods, the accurate assessment and management of volume overload in patients with decompensated heart failure remains problematic".
Congestive heart failure patients have a 30 to 40% death rate within one year of being admitted to a hospital for heart failure. The patients are routinely treated with powerful diuretic drugs and vasodilator medications to relax the blood vessels. Kidney failure is a frequent complication in this group of patients. This Mayo Clinic study was the first study to document the wide range of variability within individual patients with respect to the derangement of their total blood volume as well as their red cell volume.
The journal article was accompanied by an editorial by Dr. Stuart Katz, Helen L. and Martin S. Kimmel Professor of Advanced Cardiac Therapeutics; Dir NYULMC Heart Failure Program at New York University Medical Center. Dr. Katz was one of the senior authors of one of the first papers from Columbia Presbyterian Medical Center which documented that treatment which resulted in a patient having a normal blood volume (euvolemia) markedly improved the chance of survival of heart failure patients. Dr. Katz, in a detailed editorial, commented about the variability and heterogeneity of blood volume derangements in these patients. Dr. Katz concluded "Meanwhile, clinicians must recognize the limitations of physical assessment for the diagnosis of volume overload in heart failure patients, and should consider use of direct measurements of intravascular volume and/or intravascular pressures for better estimation of euvolemia as part of a therapeutic strategy to reduce the risk of adverse outcomes".
Heart failure patients constitute the greatest medical expense for hospitalized Medicare patients. Between 15 to 30% of such patients are readmitted within 30 days or less to the hospital. Medicare compensates hospitals on the basis of diagnostic related guidelines (DRGs) which means that hospitals receive a fixed cost for a specific condition such as heart failure whether the patient is in the hospital for 3 days or 15 days. There is a significant incentive to discharge patients as soon as possible. In response to the high percentage of readmission of heart failure patients, Medicare, in 2013, instituted new guidelines which penalize hospitals significantly for each patient readmitted within 30 days or less. Dr. Joseph Feldschuh, a cardiologist and the President of Daxor, noted that utilizing blood volume measurement during hospitalization and on an outpatient basis after hospitalization may decrease the necessity for repeat hospitalization by the application of more appropriate individualized therapy.
http://finance.yahoo.com/news/heart-failure-study-mayo-clinic-123000499.html
Recent DXR News
- Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024 • GlobeNewswire Inc. • 09/19/2024 12:00:00 PM
- Newly Published Review Highlights the Pivotal Role of Daxor’s Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management • GlobeNewswire Inc. • 09/12/2024 12:00:00 PM
- Daxor Corporation Receives $300K Matching Fund Award From Launch Tennessee • GlobeNewswire Inc. • 09/05/2024 12:00:00 PM
- Leading Central Florida Hospital Implements Daxor’s BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care • GlobeNewswire Inc. • 09/04/2024 12:30:00 PM
- Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter • GlobeNewswire Inc. • 09/03/2024 08:05:00 PM
- Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 04:15:00 PM
- Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public) • Edgar (US Regulatory) • 08/29/2024 09:27:54 PM
- Form N-CSRS - Certified Shareholder Report, Semi-Annual • Edgar (US Regulatory) • 08/29/2024 09:16:22 PM
- Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network • GlobeNewswire Inc. • 08/29/2024 12:00:00 PM
- Form 40-17G - Fidelity Bond [Rule 17G-1(g)] • Edgar (US Regulatory) • 08/23/2024 08:52:16 PM
- Form N-2 - Registration statement for closed-end investment companies • Edgar (US Regulatory) • 08/16/2024 09:23:21 PM
- Daxor Corporation Awarded $1.9M Contract by The U.S. Air Force for Development of its Next Generation Tracer System in its Point-of-Care Blood Volume Analyzer • GlobeNewswire Inc. • 08/06/2024 12:00:00 PM
- Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide • GlobeNewswire Inc. • 08/05/2024 12:00:00 PM
- Daxor Corporation Awarded New U.S. Defense Health Agency Contract for Added Capabilities to Its Point-of-Care Blood Volume Analyzer • GlobeNewswire Inc. • 07/24/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 06:46:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 10:01:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 09:54:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 09:50:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 09:46:48 PM
- Daxor Corporation’s BVA-100™ Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide • GlobeNewswire Inc. • 07/11/2024 12:00:00 PM
- Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting • GlobeNewswire Inc. • 06/18/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:10:05 PM
- Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer • GlobeNewswire Inc. • 06/05/2024 12:00:00 PM
- New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM